For example, an anti-claudin-18.2 mAb is undergoing clinical study for the use in the treatment of gastric (phase III study) and pancreatic cancer (phase II study) [NCT03504397; NCT03816163]. Here, CLDN18 is linked to pancreatic neoplasm.